A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the aging male symptoms scale

Ho, C.C.K. and Tong, S.F. and Low, W.Y. and Ng, C.J. and Khoo, E.M. and Lee, V.K.M. and Zainuddin, Z.M. and Tan, H.M. (2012) A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the aging male symptoms scale. BJU International, 110 (2). pp. 260-265. ISSN 1464-4096

Full text not available from this repository. (Request a copy)
Official URL: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-...

Abstract

OBJECTIVE To evaluate the effect of i.m. injection of testosterone undecanoate 1000 mg over 12 months on the Aging Male Symptom (AMS) scale scores in men with testosterone deficiency syndrome (TDS). PATIENTS AND METHODS A total of 120 men >40 years old with TDS (total testosterone <12 nmol/L and total AMS scores >= 27) were randomized into i.m. injection of either placebo or testosterone undecanoate 1000 mg. In all, 56 and 58 participants from the active treatment and placebo groups, respectively completed the study. An i.m. injection of either placebo or testosterone undecanoate 1000 mg was given at weeks 0, 6, 18, 30 and 48. Self-administered AMS questionnaires were completed at weeks 0, week 18 and week 48. RESULTS Improvement in the total AMS score was significantly greater in the treatment group than in the placebo group (F: 4.576, P = 0.017) over the 48-week period. The mean (SD) total AMS score was 38.46 (11.85) at baseline and 33.59 (1.69) at 48 weeks for the placebo group, and 41.73 (12.73) at baseline and 32.61 (9.67) at 48 weeks for the treatment group. The mean change in the total AMS score was -12.6 in the placebo group and -21.9 in the treatment group. The mean psychological and somatovegetative domain scores decreased significantly more in the treatment group than in the placebo group (-2.8 vs -1.2, P = 0.03; and -3.2 vs -1.8, P = 0.016). The difference in change between the randomized groups for the sexual domain scores followed the same trend, though the difference was not significant. CONCLUSION Long-acting testosterone is effective in improving health-related quality of life as assessed by the AMS scale in men with TDS.

Item Type: Article
Additional Information: Department of Primary Care Medicine, Faculty of Medicine Building, University of Malaya, 50603 Kuala Lumpur, MALAYSIA
Uncontrolled Keywords: Testosterone deficiency; hypogonadism; testosterone undecanoate; injectable; long-acting; AMS scale
Subjects: R Medicine
R Medicine > RA Public aspects of medicine
Divisions: Faculty of Medicine
Depositing User: Ms Haslinda Lahuddin
Date Deposited: 21 Oct 2014 04:07
Last Modified: 14 Jul 2017 08:11
URI: http://eprints.um.edu.my/id/eprint/10106

Actions (login required)

View Item View Item